Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Covington
Chinese Patent Office
Dow
Cipla
US Army
McKinsey
Argus Health
AstraZeneca

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 010251

« Back to Dashboard

NDA 010251 describes INVERSINE, which is a drug marketed by Targacept and is included in one NDA. Additional details are available on the INVERSINE profile page.

The generic ingredient in INVERSINE is mecamylamine hydrochloride. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the mecamylamine hydrochloride profile page.
Summary for 010251
Tradename:INVERSINE
Applicant:Targacept
Ingredient:mecamylamine hydrochloride
Patents:0
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 010251

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Cipla
US Department of Justice
Moodys
Mallinckrodt
Express Scripts
Fish and Richardson
Daiichi Sankyo
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.